ArticleInternational journal of nanomedicine2020
Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Development and characterization of ivermectin nanoformulations for topical acaricidal activity against Rhipicephalus sanguineus ticks.Scientific reports · 2026Article
- Inhibition of Biofilm Formation by Respiratory Bacterial Pathogens via Silver Nanoparticles and Functionalized HEPA Filters.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Paradoxical Features Empower Biogenic Silver Nanoparticles.Molecules (Basel, Switzerland) · 2025Review
- Article
- Phytofabrication of silver nanoparticles usingNanoscale advances · 2023Article
- Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy.Cells · 2023Review
- Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Green Synthesis of Silver Nanoparticles Loaded Hydrogel for Wound Healing; Systematic Review.Gels (Basel, Switzerland) · 2023Review
- Multidrug-Resistant Pathogens in Burn Wound, Prevention, Diagnosis, and Therapeutic Approaches (Conventional Antimicrobials and Nanoparticles).The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Review
- Prevalence and Molecular Characterization of Methicillin-ResistantJournal of microbiology and biotechnology · 2022Article
- Article
- Ciprofloxacin-Loaded Silver Nanoparticles as Potent Nano-Antibiotics against Resistant Pathogenic Bacteria.Nanomaterials (Basel, Switzerland) · 2022Article
- Biogenic Silver Nanoparticles as a Stress Alleviator in Plants: A Mechanistic Overview.Molecules (Basel, Switzerland) · 2022Review
- Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review.ACS applied nano materials · 2022Review
- Antimicrobial Efficacy of Glass Ionomer Cement in Incorporation with BiogenicMolecules (Basel, Switzerland) · 2022Article
- Article
- Green Synthesis of Copper Nano-Drug and Its Dental Application upon Periodontal Disease-Causing Microorganisms.Journal of microbiology and biotechnology · 2021Article
- Well-Orientation Strategy Biosynthesis of Cefuroxime-Silver Nanoantibiotic for Reinforced Biodentine™ and Its Dental Application againstMolecules (Basel, Switzerland) · 2021Article
- Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation.Journal of nanobiotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDue to the expanded bacterial genetic tolerance to antibiotics through different mechanisms, infectious diseases of MDR bacteria are difficult for treatment. Consequently, we synthesized drug conjugated nanoparticles to dissolve this problem. Moreover, the present study aims to display the cell death status treated with cefotaxime-CS-AgNPs and also, apoptosis pathways of human RPE-1 normal cells and human MCF-7 breast cancer cells.
methodsHere, we demonstrate the possibility to synthesize AgNPs and conjugate them with cefotaxime to survey the probability of cefotaxime-CS-AgNPs as an antimicrobial agent against cefotaxime-resistant strains
resultsTEM showed the size of AgNPs, CS-AgNPs and cefotaxime-CS-AgNPs ranged from 7.42 to 18.3 nm, 8.05-23.89 nm and 8.48-25.3 nm, respectively, with a spherical shape. The cefotaxime-CS-AgNPs enhanced the high antimicrobial properties compared to AgNPs or pure antibiotic. The MIC of Cefotaxime-CS-AgNPs ranged from 3 µg/mL to 8 µg/mL against tested
conclusionResults enhanced the conjugating utility in old unresponsive cefotaxime to AgNPs to restore its efficiency against previous strains and demonstrated potential therapeutic applications of cefotaxime-CS-AgNPs. Moreover, this research gives remarkable insights for designing nanoscale delivery and curative systems that have a pronounced cytotoxic activity on cancer cells and are safe to normal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.